{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:04:18Z","timestamp":1761743058752,"version":"3.40.5"},"reference-count":10,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,3,1]]},"abstract":"<jats:p>Our patient with mucopolysaccharidosis type VI received enzyme replacement therapy with recombinant human arylsulfatase B (galsulfase [Naglazyme, BioMarin Pharmaceutical Inc, Novato, CA]) shortly after approval by the US Food and Drug Administration. After 1 month of weekly infusions, the patient developed significant infusion-associated reactions and could not tolerate therapy at the recommended infusion rate. We were able to continue treatment successfully by the addition of steroids to the premedication regimen and by significantly reducing the rate of drug infusion. Over the next several months, the patient's infusion rate was slowly increased and the premedications were weaned. We demonstrate that by significantly reducing the rate of infusions and adjusting the premedication regimen, galsulfase infusions can continue with no additional observance of infusion-associated reactions.<\/jats:p>","DOI":"10.1542\/peds.2007-0665","type":"journal-article","created":{"date-parts":[[2008,2,5]],"date-time":"2008-02-05T01:34:28Z","timestamp":1202175268000},"page":"e714-e717","source":"Crossref","is-referenced-by-count":24,"title":["Successful Management of Difficult Infusion-Associated Reactions in a Young Patient With Mucopolysaccharidosis Type VI Receiving Recombinant Human Arylsulfatase B (Galsulfase [Naglazyme])"],"prefix":"10.1542","volume":"121","author":[{"given":"Katherine H.","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Genetics, Birth Defects, and Metabolism, Children's Memorial Hospital, Chicago, Illinois"},{"name":"Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celeste","family":"Decker","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical Inc, Novato, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara K.","family":"Burton","sequence":"additional","affiliation":[{"name":"Division of Genetics, Birth Defects, and Metabolism, Children's Memorial Hospital, Chicago, Illinois"},{"name":"Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2008,3,1]]},"reference":[{"key":"2021120905473461200_R1","doi-asserted-by":"crossref","unstructured":"Meikle, PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA.1999;281(3):249\u2013254","DOI":"10.1001\/jama.281.3.249"},{"key":"2021120905473461200_R2","doi-asserted-by":"crossref","unstructured":"Baehner F, Schmiedeskamp C, Krummenauer F, et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis.2005;28(6):1011\u20131017","DOI":"10.1007\/s10545-005-0112-z"},{"key":"2021120905473461200_R3","doi-asserted-by":"crossref","unstructured":"Poorthuis BJHM, Wevers RN, Kleijer WJ, et al. The frequency of lysosomal storage diseases in the Netherlands. Hum Genet.1999;105(1\u20132):151\u2013156","DOI":"10.1007\/s004399900075"},{"key":"2021120905473461200_R4","doi-asserted-by":"crossref","unstructured":"Nelson J, Crowhurst J, Carey B, Greed L. Incidence of the mucopolysaccharidoses in western Australia. Am J Med Genet A.2003;123(3):310\u2013313","DOI":"10.1002\/ajmg.a.20314"},{"key":"2021120905473461200_R5","doi-asserted-by":"crossref","unstructured":"Azevedo ACMM, Schwartz IV, Kalakun L, et al. Clinical and biochemical study of 28 patients with mucopolysaccharidosis type VI. Clin Genet.2004;66(3):208\u2013213","DOI":"10.1111\/j.1399-0004.2004.00277.x"},{"key":"2021120905473461200_R6","doi-asserted-by":"crossref","unstructured":"Nyhan WL, Barshop BA, Ozand PT. Atlas of Metabolic Diseases. 2nd ed. New York, NY: Oxford University Press;2005","DOI":"10.1201\/b13565"},{"key":"2021120905473461200_R7","doi-asserted-by":"crossref","unstructured":"Herskhovitz E, Young E, Rainer J, et al. Bone marrow transplantation for Maroteaux-Lamy syndrome (MPS VI): long-term follow up. J Inher Metab Dis.1999;22(1):50\u201362","DOI":"10.1023\/A:1005447232027"},{"key":"2021120905473461200_R8","doi-asserted-by":"crossref","unstructured":"Harmatz P, Whitley CB, Waber L, et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr.2004;144(5):574\u2013580","DOI":"10.1016\/j.jpeds.2004.03.018"},{"key":"2021120905473461200_R9","doi-asserted-by":"crossref","unstructured":"Harmatz P, Ketteridge D, Giugliani R, et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics.2005;115(6). Available at: www.pediatrics.org\/cgi\/content\/full\/115\/6\/e681","DOI":"10.1542\/peds.2004-1023"},{"key":"2021120905473461200_R10","doi-asserted-by":"crossref","unstructured":"Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or RHASB) and follow-on, open-label extension study. J Pediatr.2006;148(4):533\u2013539","DOI":"10.1016\/j.jpeds.2005.12.014"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/3\/e714\/1122183\/zpe0030800e714.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/3\/e714\/1122183\/zpe0030800e714.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T23:21:43Z","timestamp":1639092103000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/121\/3\/e714\/72795\/Successful-Management-of-Difficult-Infusion"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,1]]},"references-count":10,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2008,3,1]]},"published-print":{"date-parts":[[2008,3,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2007-0665","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"type":"print","value":"0031-4005"},{"type":"electronic","value":"1098-4275"}],"subject":[],"published":{"date-parts":[[2008,3,1]]}}}